Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESMO 2024 | IMMUNOSARC II: sunitinib and nivolumab in the clear cell sarcoma cohort

Javier Martin-Broto • 16 Sep 2024
ESMO 2024
Sarcoma Antibodies Checkpoint Inhibitors Nivolumab Sunitinib
IMMUNOSARC II

Javier Martin-Broto, MD, PhD, Hospital Universitario Fundación Jiménez Díaz, Madrid, Spain, discusses the Phase II IMMUNOSARC II master trial (NCT03277924) of nivolumab and sunitinib in patients with advanced clear cell sarcoma (CCS). Encouraging median and 6-month progression-free survival (PFS) rates were reported. The combination also demonstrated manageable toxicity, suggesting nivolumab and sunitinib could offer a new treatment option for CCS, pending further studies. This interview took place at the European Society for Medical Oncology (ESMO) 2024 Congress in Barcelona, Spain.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Javier Martin-Broto

Risk stratification with nomograms improves decision-making in localized sarcoma
4:04
Risk stratification with nomograms improves decision-making in localized sarcoma
Javier Martin-Broto • 5 May 2025
Understanding the role of TLS in sarcoma treatment: a key to unlocking immunotherapy potential
6:46
Understanding the role of TLS in sarcoma treatment: a key to unlocking immunotherapy potential
Javier Martin-Broto • 5 May 2025
Overcoming sarcoma's cold microenvironment with immunotherapy combinations
6:53
Overcoming sarcoma's cold microenvironment with immunotherapy combinations
Javier Martin-Broto • 5 May 2025
From cold tumors to hot targets: immunotherapy advances in sarcoma treatment
2:57
From cold tumors to hot targets: immunotherapy advances in sarcoma treatment
Javier Martin-Broto • 5 May 2025

Related Videos

Using spatial RNA-protein profiling to identify ADC targets in LMS
1:20
Using spatial RNA-protein profiling to identify ADC targets in LMS
Carlos Torrado • 1 Jun 2026
ctDNA monitoring for recurrence in bone and soft tissue sarcoma
0:58
ctDNA monitoring for recurrence in bone and soft tissue sarcoma
Maggie Zhou • 1 Jun 2026
ctDNA improves detection and prognostication of sarcoma recurrence
0:45
ctDNA improves detection and prognostication of sarcoma recurrence
Maggie Zhou • 1 Jun 2026
Sarcoma highlights at ASCO 2026: SARC-041, PEAK, and RINGSIDE
1:00
Sarcoma highlights at ASCO 2026: SARC-041, PEAK, and RINGSIDE
Maggie Zhou • 1 Jun 2026
The content of VJOncology is intended for healthcare professionals